The levels of interleukin (IL)-18, IL- 6, and tumor necrosis factor-α are increased in patients undergoing CRS with HIPEC.25,26 Surgical stress and immunosuppression from the hematologic toxicities of MMC might further delay wound healing and postoperative recovery.27 Considering that postoperative complications worsen oncologic outcomes24, the MMC dose should be optimized, and postoperative complications should be prevented during the neutropenia period after CRS with HIPEC. The gene discussed is IL18; the disease is Decreased total neutrophil count.